We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Brain Chemical Restores Myelin in Mouse Model of MS

Two neurons making a connection.
Credit: iStock

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Brain Chemical Restores Myelin in Mouse Model of MS"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

A University of Alberta researcher is one step closer to demonstrating the potential of a brain molecule called fractalkine to halt and even reverse the effects of multiple sclerosis and other neurodegenerative diseases.


Multiple sclerosis is an autoimmune disease in which the myelin, or fatty lining of nerve cells, is eroded, leading to nerve damage and slower signalling between the brain and the body. MS symptoms range from blurred vision to complete paralysis, and while there are treatments, the causes are not fully understood and nothing exists to reverse the disease process. More than 90,000 Canadians live with MS, according to the MS Society.


In new research published in Stem Cell ReportsAnastassia Voronova, assistant professor in the Faculty of Medicine & Dentistry and Canada Research Chair in Neural Stem Cell Biology, injected fractalkine into mice with chemically induced MS.


She found the treatment increased the number of new oligodendrocytes — vital brain and spinal cord cells that produce myelin in both embryonic and adult brains — which are damaged during the MS autoimmune attack.


“If we can replace those lost or damaged oligodendrocytes, then they could make new myelin and it is believed that would halt the disease progression, or maybe even reverse some of the symptoms,” Voronova says. “That's the Holy Grail in the research community and something that we're very passionate about.”

Hoping to meet an unmet need

Voronova’s earlier research tested the safety and efficacy of fractalkine in normal mice and found similar beneficial effects. Other researchers have demonstrated that fractalkine may provide protection for nerves in mouse models before the disease is induced, but this is the first time it has been tested on animals that already have the disease.


“What was important to us is to approximate it to the clinic,” Voronova points out. “When a person with MS is diagnosed, the injury has already occurred, there's some kind of attack that has already happened on the oligodendrocytes and myelin.”


Voronova and her team observed new oligodendrocytes, as well as reactivated progenitor cells that can regenerate oligodendrocytes, in the brains of the treated animals. Remyelination occurred in both the white and grey matter. The researchers also observed a reduction in inflammation, part of the damage caused by the immune system.


Next steps for the treatment include testing it in other diseased mouse models, including those with neurodegenerative diseases other than MS. Voronova is working with colleagues at the U of A to search for ways to easily deliver fractalkine to the brain, such as through a nasal spray. Voronova is a developmental and stem cell biologist by training, so she also hopes to test and develop other brain molecules that she originally discovered while doing basic research on the embryonic brain.


“We've made a lot of progress in the medical and research communities on disease-modifying therapies for multiple sclerosis, but what we really don't have — and is an unmet need in the multiple sclerosis community — is regenerative therapies for the central nervous system,” Voronova says.


Reference: Almeida MMA de, Watson AES, Bibi S, et al. Fractalkine enhances oligodendrocyte regeneration and remyelination in a demyelination mouse model. Stem Cell Reports. 2023;0(0). doi:10.1016/j.stemcr.2022.12.001


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement